Shots:

• Dova Pharmaceuticals to pay Salix Pharmaceuticals- a quarterly fee on the US sales. Salix to deploy ~100 specialists for promotion of Doptelet which is expected to launch in mid-Oct 2018
• Doptelet is approved by FDA on 21 May- 2018 for thrombocytopenia in adult patients with chronic liver disease (CLD). The approval is based on P-III ADAPT-1 and ADAPT-2 trials administering 40mg or 60 mg of Doptelet vs PBO- testing safety and efficacy
• Doptelet (avatrombopag) is once-daily orally administered- second generation TPO receptor agonist- a primary regulator of normal platelet production

Ref: Dova Pharmaceuticals  | Image: Wraltechwire